Invitrogen Herceptin candidate Dx launches
This article was originally published in The Gray Sheet
Executive Summary
Firm taps Biocare Medical to distribute its SPOT-Light HER2 test. The kit was PMA approved July 8 for use as an aid to assess which breast cancer patients might benefit from treatment with Genentech's Herceptin therapy (1"The Gray Sheet" July 14, 2008, p. 17). "Working with the Biocare sales force, we believe we will be able to more rapidly and efficiently deliver this critical diagnostic," Invitrogen said
You may also be interested in...
Invitrogen: New Herceptin Candidate Dx Gives More Labs A Chance To Test
Invitrogen's SPOT-Light HER2 test, PMA-approved by FDA July 8, will not be the first kit in the U.S. to help physicians decide if a breast cancer patient will benefit from Genentech's Herceptin therapy, but it will allow a host of new laboratories to perform the analysis, according to the firm
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.